Search

Tristeza disease is caused by citrus tristeza virus (CTV) expresses salient symptoms like stem pitting, yellowing of leaves, stunted growth of large, small lateral branches and twigs. The study was carried out to quantify the spatial and temporal distribution of CTV disease in major citrus growing areas of Sargodha district (Sargodha, Kot Momin, and Bhalwal). The samples from the declined orchards were collected based on symptomology and confirmed through ELISA. CTV was detected in 3 varieties viz., Kinnow (Citrus reticulate), Mosambi (Citrus sinensis) and Feutrell's early (Citrus reticulate cv feutrell's early). The maximum disease incidence was recorded in Mosambi (90%), followed by Feutral's early (74%) and Kinnow (57%). Mosambi was the most susceptible within the range of OD values (0.82-2.35) followed by Feutrell's early (0.45-0.64) and Kinnow (0.25-0.56). The disease severity was recorded only on Mosambi as it was more affected than Feutral's early and Kinnow. The rating scale to observe the severity of tristeza disease was based on percentage of pits in the 1 sq. inch piece of bark at bud union of infected tree. This rating scale has been developed for the first time to record the tristeza disease severity. The maximum disease severity was recorded in Kot Momin (62%) followed by Bhalwal (56%) and Sargodha (50%). The study concluded that CTV is one of the most promising factors playing role in the citrus decline. [ABSTRACT FROM AUTHOR]

Tristeza disease is caused by citrus tristeza virus (CTV) expresses salient symptoms like stem pitting, yellowing of leaves, stunted growth of large, small lateral branches and twigs. The study was carried out to quantify the spatial and temporal distribution of CTV disease in major citrus growing areas of Sargodha district (Sargodha, Kot Momin, and Bhalwal). The samples from the declined orchards were collected based on symptomology and confirmed through ELISA. CTV was detected in 3 varieties viz., Kinnow (Citrus reticulate), Mosambi (Citrus sinensis) and Feutrell’s early (Citrus reticulate cv feutrell’s early). The maximum disease incidence was recorded in Mosambi (90%), followed by Feutral’s early (74%) and Kinnow (57%). Mosambi was the most susceptible within the range of OD values (0.82-2.35) followed by Feutrell’s early (0.45-0.64) and Kinnow (0.25-0.56). The disease severity was recorded only on Mosambi as it was more affected than Feutral’s early and Kinnow. The rating scale to observe the severity of tristeza disease was based on percentage of pits in the 1 sq. inch piece of bark at bud union of infected tree. This rating scale has been developed for the first time to record the tristeza disease severity. The maximum disease severity was recorded in Kot Momin (62%) followed by Bhalwal (56%) and Sargodha (50%). The study concluded that CTV is one of the most promising factors playing role in the citrus decline. [ABSTRACT FROM AUTHOR]

Background: Regardless of amazing advancements in contemporary science & technology, it is not possible to provide everyone access to high-quality healthcare. Traditional medicine, in particular Ayurveda and Unani medicine, is regarded as a major global provider of healthcare. This manuscript is aimed to provide the promulgation of Unani Medicine in contemporary healthcare system. Methods: A in-depth literature analysis was successfully carried out from year 2006 to 2021 to collate the information on the advancement, growth and development of the Unani System of Medicine (USM). The search strategy was performed with recent surveys, articles and the numerous initiatives undertaken by the Ministry of AYUSH, Centre council in research in unani medicine (CCRUM) & other institutions on Unani education and research. Additionally, the updated market analysis (2020-2022) comprises import, export and trade data on Unani medicines is also described. From what we know, this review is the first of a kind to describe the domestic and global perspective of Unani medicine with and its global development. Results: The multi-disciplinary, multi-centric research initiatives of the Ministry of AYUSH have resulted in an increase in medical facilities and education in the Unani System of Medicine. With 1748 Unani dispensaries and 3947 beds in Unani hospitals, the number of these facilities has grown at a 2.4% annual pace between 2011 and 2021. Conclusion: There is tremendous growth in Unani as well as in herbal industry. Unani Medicines have shown their potential and need for better drugs and remedies against various diseases. The knowledge on import and export and the information on research and education enable to work more in this domain. These initiatives favour the World Health Organisation advocating Unani medicine as a better alternative system against various diseases. [ABSTRACT FROM AUTHOR]

Objectives: The study aimed to establish the effectiveness of Unani add-on regimen by comparing theduration required for change in disease status from COVID-19 positive asymptomatic / mildto moderate symptomatic patients to asymptomatic negative. Methods: This single-centric, randomized, twin arm, controlled, clinical trial was carried out on a totalnumber of 62 RT-PCR confirmed COVID-19 patients. The Intervention group (IG) receivedUnani Regimen (Khameera Marwareed and Unani Joshanda) in addition to the conventional management, while the Control group (CG) received only conventional management. Results: It was observed that 16 (51.6%) patients in Intervention Group and 3 (9.4%) patients incontrol group became negative for COVID-19 at day 7 and remaining 13 out of 15 (93.5%) patients in Intervention Group and 20 out of 28 (74.1%) patients in control group becamenegative for COVID-19 at day 14. This effect of the Unani Regimen in comparison to thecontrol group was statistically significant (p =0.003). Conclusions: It can be concluded that the change of COVID-19 positive asymptomatic / mild to moderate symptomatic patients to RT-PCR negative was much earlier in the add-on Unani regimen group as compared to control group. [ABSTRACT FROM AUTHOR]

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread globally. COVID-19 presents varied clinical features. The present study focuses on number of patients turning COVID-19 positive, change in Immune Status Questionnaire (ISQ) and WHO quality of life- Bref (WHO Qol – BREF) scales after taking intervention. This open labelled, double arm, controlled, interventional, clinical trial was conducted on high-risk individuals i.e., those residing with a COVID-19 positive member in the identified quarantine area. This twin armed study was conducted on asymptomatic individuals exposed to COVID -19. The test group were prescribed Unani poly-herbal decoction together with Unani formulations Khamira Marwareed and Tiryaq e Arba whereas the control group was not on any intervention. The duration of intervention was 20 days; follow ups were planned on day 10 and day 20. Of the 81 participants enrolled, none of the patients turned COVID-19 positive. However, 13.58% (n=11) developed COVID like symptoms and 70 patients completed the study. The mean age of the participants was 41.42±16.9 years; however, majority of the participants were 18-28 years male with Damvi (Sanguine) temperament. The quality of life of the intervention group improved significantly however, the immune status in both the groups increased with P <0.001. The Unani prophylactic regimen provides a 62% (relative risk reduction) protection against COVID -19. This pilot study paves for a study on a larger population. No adverse effects were observed during the study. Absence of biochemical investigations were limitations to the study. [ABSTRACT FROM AUTHOR]

Evolvulus alsinoides L. (Sankhaholi) has been traditionally used in Unani (Greco-Arabic) medicine to treat diverse cardiovascular disorders. Notably, preclinical and clinical investigations have substantiated its remarkable potential as an antihypertensive agent. The aim of this study was to compare the efficacy of hydroalcoholic extract of Evolvulus alsinoides L. and ramipril in treating hypertension using a higher dose of the test drug within the recommended limit. In this open-label randomized controlled trial, 57 participants (29 in the test group, 28 in the control group) completed the 42-day study. The test group received 630 mg of dried hydro-alcoholic extract of Evolvulus alsinoides L. in capsule form orally once daily, while the control group received 5 mg of Ramipril orally once daily. Participants in both groups were advised to adhere to the Dietary Approaches to Stop Hypertension (DASH) eating plan in terms of diet and lifestyle adjustments recommended by JNC-8. The primary outcome measures were changes in systolic and diastolic blood pressure as well as changes in plasma levels of hsCRP and IL6. Secondary outcome measures included changes in symptoms such as palpitations, giddiness, headaches, fatigue and shortness of breath. Headaches, palpitations, and giddiness were assessed using a customized Visual Analog Scale (VAS) graded as "none," "mild," "moderate," and "severe". Fatigue was assessed on a binary scale as either absent or present, and dyspnea was assessed using the modified Medical Research Council (mMRC) scale for breathlessness. Both primary and secondary outcomes were assessed at baseline and each follow-up visit (2nd week, 4th week, and 6th week) until the completion of the trial. At the end of the trial, the mean differences for the primary outcomes were as follows:SBP: − 1.88 95 % C I : − 4.82 , 1.05 , p = 0.203 , d = 0.33 , DBP: − 2.83 95 % C I : − 4.67 , − 0.10 , p = 0.003 , d = 0.8 , hsCRP: − 1.40 95 % C I : − 2.80 , − 0.003 , p = 0.49 , d = 0.53 , and IL6: − 88.67 95 % C I : − 148.90 , − 28.43 , p = 0.005 , d = 0.78 . No statistically significant differences were observed between the two groups for any of the secondary outcomes. Based on the preliminary results, it can be inferred that the hydro-alcoholic extract of Evolvulus alsinoides L. exhibits significant antihypertensive potential, comparable to that of ramipril. Furthermore, it appears that Evolvulus alsinoides L. may be more effective than ramipril in reducing the biochemical markers of inflammation associated with primary hypertension. However, additional research is required to validate these findings. [Display omitted] • Evolvulus alsinoides L. (Sankhaholi) is used in Unani medicine for treating various cardiovascular conditions. • The study evaluates Evolvulus alsinoides L. extract for primary hypertension, using a higher dose within recommended limits. • Test group received 630 mg of E. alsinoides extract, while control group took 5 mg of Ramipril, both once daily for 42 days. • Study concludes hydroalcoholic extract of E. alsinoides has significant antihypertensive potential, comparable to Ramipril. [ABSTRACT FROM AUTHOR]

To evaluate the effect of Maghz-e-Jamun (Eugenia jambolana) on blood sugar and insulin levels in prediabetic stage (Intermediate hyperglycemic state). It was randomized, single blind, placebo controlled study of 52 prediabetic patients (diagnosed according to ADA classification) randomly allocated in test and control group. Maghz-e-Jamun (Eugenia jambulana) powder 4.5g was filled in 6 capsules, 3 capsules was given orally twice a day for 12 weeks in test group. Whereas, in control group, placebo prepared with starch was given in the same form and dosage as in test group for the same duration. During the protocol therapy, patient in both the groups were asked to follow the prescribed diet as provided by dietician. Patients were also asked to take brisk walk in morning daily for 40 minutes. FBS, BSPP was assessed on baseline, 28th day and 84th day of therapy, while HbA1c, Serum insulin Fasting and HOMA-IR were assessed after 12 weeks. For the assessment of safety of the drug and placebo, complete haemogram, LFT, KFT and Urine R/M was done on baseline, 28th day and 84th day of the study. Significant reduction in FPG from (105.67 ±2.20) to (96.03 ±1.94) were noted after 28th day in prediabetics with p value 0.001**, the FPG further declined to (92.13±1.50) after 84th day of follow up in the test group in which powder of the seeds of Eugenia jambolana were given. BSPP declined from (130.33±3.44) to (118.83± 2.65) after 28 day and become (121.93±3.16) after 84 day with p value 0.012* and 0.071 respectively. Highly significant reduction in value of HbA1c was revealed from (5.82±0.09) to (5.55±0.08) with p value 0.001**. As far as level of serum insulin fasting is concerned, no changes in insulin level was found after 84 day of administration of Maghz-e-Jamun (Eugenia jambolana) in prediabetics. Slight reduction in value of HOMA-IR was found before and after the intervention i.e., (2.85±0.25) from (3.05±0.30). No significant changes are revealed after 28 days as well after 84 days of intervention in safety profiles laboratory investigations which are complete haemogram, LFT, KFT and Urine R/M. Maghz-e-Jamun (Eugenia jambolana) exhibited good glucose control in prediabetic condition. It can also revert the prediabetic condition into normoglycemia and prevent the conversion of prediabetic condition into Type 2 diabetes if supported with dietary intervention and exercise. [ABSTRACT FROM AUTHOR]

Today the world is witnessing a rise in incidence of diseases and the demand for affordable health care has increased manifold. An effective and robust public health system is the need of the hour to improve the health and wellbeing of people across the globe. Unani Medicine is a holistic system of medicine, which offers indigenous and effective therapies, which are already helping millions of people across the globe in living a healthy life. Unani medicine gained momentum as an effective alternative to conventional medicine due to its systematic approach towards diagnosis and treatment of diseases, effective management of lifestyle disorders and primary focus on prevention of ailments. This system of medicine, which has its origin from Greece, today has a presence in many parts of the globe. Besides India, it is practiced in several countries like Bangladesh, South Africa, Pakistan, Iran, United Arab Emirates and Sri Lanka etc. The Government of India facilitated the growth and development of Unani medicine by recognizing its utility and scope and integrated it into healthcare delivery system. With its wide network of quality educational institutions, comprehensive healthcare facilities, state of the art research institutions and quality drug manufacturing industries and on account of its utilization by a large number of people for their healthcare needs, India has emerged as the global leader in Unani medicine. Concerted efforts are being made to carry out high quality, evidence based research and to make the system more accessible and affordable. Unani medicine can contribute a wealth of knowledge and experience for the benefit of human kind and has the potential to be one of the major contributors in health care delivery in other parts of the globe. [ABSTRACT FROM AUTHOR]

This study concerns wide angular sector (higher order) null synthesis in planar irregular sparse antenna arrays when aperture distributed sub-arrays are used to reduce the computational load. A hybrid optimisation tool has been used to find array element excitations to achieve as low as possible sector nulls for the desired sector width. Performance comparisons have been made for three sub-array configurations based on the obtained numerical results. Various interference jamming scenarios have been considered including single and dual sectors for single-dimensional (θ) (1D) and two-dimensional (θ, ϕ) (2D) nulls. The proposed optimisation scheme has shown to be successful for the synthesis of 1D and 2D sector nulls with depths as low as -100 dB for the given configuration with reduced computational time when compared with the full array. The comparison of achieved null depths for different sub-array sizes and convergence time has also been presented and discussed. [ABSTRACT FROM AUTHOR]

Naturally, existing lignocelluloses fibers showed outstanding potential in paper industry and other conventional applications. On the other hand, lignocellulose fibers are suitable candidate for high-tech applications under the scope of abundance, flexibility, light-weight and environment friendliness. In this study, paper sheets were prepared from lignocelluloses fibers extracted from self-growing plant, typha angustifolia. Lignocelluloses paper sheets were characterized for scanning electron microscopy (SEM), universal testing machine (UTM) and vector network analyzer (VNA). Flexible paper sheets displayed a tensile strength of 9.1 MPa and further used as a substrate in patch antenna to observe dielectric characteristics. The patch antenna is designed at 5.1 GHz which showed return loss less than −10 dB and dielectric constant 3.71. The use of lignocelluloses paper sheet as a substrate in patch antenna will provide the opportunity of miniaturization of size and weight in comparison of a jean substrate based antenna. [ABSTRACT FROM AUTHOR]

Aim of the Study: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters. Materials and Methods: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group 'A' thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group 'B' thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group 'C' 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters. Results: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well. [ABSTRACT FROM AUTHOR]

Sparse antenna arrays with irregularly spaced elements are increasingly being used in large array applications such as radio astronomy and radar. These antenna arrays may consist of hundreds of elements and therefore optimisation of these arrays becomes computationally expensive. This study proposes a novel solution to the problem of null synthesis in such arrays, where nulls are formed in prescribed locations for two-dimensional irregular sparse antenna arrays. The technique is based on a subarray and hybrid synthesis solution, where each subarray spans the entire antenna aperture. Single and multiple null formations with array gain maximisation are considered. The technique's effectiveness is demonstrated using evolutionary optimisation algorithms; however, the basic technique can be used with other optimisation methods. The simulation results presented compare the null synthesis performance with and without subarraying and it has shown that the use of subarray results in improved convergence compared with a direct full array synthesis. Furthermore the technique is appropriate for ready application to parallel computer architectures. [ABSTRACT FROM AUTHOR]

The study aimed to evaluate the effect of cupping therapy at a clinical setting for knee osteoarthritis. A randomized, controlled clinical trial was conducted. Cupping was performed on 0-6th day; 9-11th day and 14th day, i.e., 11 sittings follow-up to determine longer term carryover of treatment effects utilizing both objective and subjective assessment. The assessment was performed before and after treatment spreading over a period of 15 days. The results of this study shows significant and better results in the overall management of knee osteoarthritis, particularly in relieving pain, edema, stiffness and disability. The efficacy of treatment with cupping therapy in relieving signs and symptoms of knee osteoarthritis is comparable to that of acetaminophen 650 mg thrice a day orally, in terms of analgesia, anti-inflammatory and resolution of edema with minimal and temporary side-effects like echymosis and blister formation while as control drug has greater side-effects particularly on upper gastrointestinal tract. It is recommended that further studies are conducted with a larger study samples and of longer duration. [ABSTRACT FROM AUTHOR]

The aim of this study is to evaluate the efficacy of a Unani formulation in hypertension. A total of 90 patients with total cholesterol level of more than 220 mg/dl with associated conditions were included in this study. A total of 30 patients having a mean systolic blood pressure (BP) of 133.86 mmHg comprising Group A received Unani formulation Safoof-e-Muhazzil (SM) in its classical powder form in the dose of 5 g twice a day orally. Group B comprising of 30 patients with a mean systolic BP of 133.13 mmHg received same drug, but in compressed tablet form in the same dosage, whereas, 30 patients comprising Group C with a mean systolic BP of 129.45 mmHg, received Atorvastatin 10 mg as a standard control. Patients were evaluated on each follow-up at 2nd, 4th and 6th week. The mean systolic BP in Group A and B before treatment was 133.86 ± 3.028 mmHg and 133.13 ± 2.852 mmHg, which significantly decreased to 119.33 ± 1.922 mmHg (P < 0.001) and 119 ± 1.760 mmHg (P < 0.001) respectively. In the control Group C before treatment BP was 129.45 ± 2.499 mmHg and after treatment it significantly decreased to 124.34 ± 1.794 mmHg (P < 0.01). The percentage change after treatment was 10.85%, 10.61% and 3.94% respectively in each group. Mean diastolic BP in Group A and B before treatment was 85.06 ± 2.11 mmHg and 84.56 ± 1.5 mmHg, which significantly decreased to 79.06 ± 1.56 mmHg (P < 0.001) and 79.96 ± 1.15 mmHg (P < 0.001) respectively, BP before treatment in Group C was 83.23 ± 1.588 mmHg, which was decreased to 124.34 ± 1.794 mmHg (P < 0.01). The study results indicate that the test drug was quite effective in reducing both systolic as well as diastolic BP. [ABSTRACT FROM AUTHOR]

ABSTRACT Reduced size dual band patch antenna is designed on pulp fibers-based substrate, obtained from a self-growing plant, Typha angustifolia. The proposed design is low cost and has <10 dB return loss at 2.4 and 5.7 GHz, with 6.9 dBi antenna gain and also has potential for conformal designs. © 2016 Wiley Periodicals, Inc. Microwave Opt Technol Lett 58:2146-2148, 2016 [ABSTRACT FROM AUTHOR]

Summary: Quadrifilar helix antenna (QHA) has its applications in satellite communications. This paper presents the performance optimisation of input and radiation characteristics of QHA in the presence of infinite and finite metallic ground planes. For the infinite ground plane, it has been observed that input parameters such as impedance and voltage standing wave ratio (VSWR) are stable, and the antenna has broader half power beamwidth (HPBW). Smaller metallic platforms that act as finite ground planes produce better 3‐dB axial ratio beamwidth and boresight axial ratio. Deployment of QHA on smaller metallic platforms such as nanosatellites and CubeSats enhances the circularly polarised beamwidth of the antenna with improved boresight axial ratio. However, on large low earth orbit (LEO) satellites, stable input characteristics and broader HPBW have been achieved at the cost of narrow circularly polarised beamwidth and degraded boresight axial ratio. [ABSTRACT FROM AUTHOR]

Biogenic silver nanoconjugates (AgNCs), derived from medicinal plants, have been widely explored in the field of biomedicines. AgNCs for the first-time were synthesized using ethyl acetate seed extracts of Abrus precatorius and their antiproliferative and antiangiogenic efficacies were evaluated against cervical and oral carcinoma. Ultraviolet–Visible spectrophotometry, dynamic light Scattering (DLS), and scanning electron microscopy (SEM) were used for characterization of AgNCs. Antiproliferative activity was investigated using MTT, DNA fragmentation and in-vitro antioxidant enzyme activity assays. In-vivo chick chorioallantoic membrane (CAM) model was used to evaluate antiangiogenic activity. A total of 11 compounds were identified in both the extracts in GCMS analysis. The synthesized AgNCs were spherical shaped with an average size of 97.4 nm for AgAPE (Sox) and 64.3 nm for AgAPE (Mac). AgNCs possessed effective inhibition against Hep2C and KB cells. In Hep2C cells, AgAPE (Mac) revealed the highest SOD, catalase, GST activity and lower MDA content, whereas AgAPE (Sox) showed the highest GSH content. On the other hand, in KB cells, AgAPE (Sox) exhibited the higher SOD, GST activity, GSH content, and least MDA content, while AgAPE (Mac) displayed the highest levels of catalase activity. Docking analysis revealed maximum binding affinity of safrole and linoleic acid with selected targets. AgAPE (Sox), AgAPE (Mac) treatment profoundly reduced the thickness, branching, and sprouting of blood vessels in the chick embryos. This study indicates that A. precatorius-derived AgNCs have enhanced efficacies against cervical and oral carcinoma as well as against angiogenesis, potentially limiting tumour growth. [ABSTRACT FROM AUTHOR]

Biogenic silver nanoconjugates (AgNCs), derived from medicinal plants, have been widely explored in the field of biomedicines. AgNCs for the first-time were synthesized using ethyl acetate seed extracts of Abrus precatorius and their antiproliferative and antiangiogenic efficacies were evaluated against cervical and oral carcinoma. Ultraviolet–Visible spectrophotometry, dynamic light Scattering (DLS), and scanning electron microscopy (SEM) were used for characterization of AgNCs. Antiproliferative activity was investigated using MTT, DNA fragmentation and in-vitro antioxidant enzyme activity assays. In-vivo chick chorioallantoic membrane (CAM) model was used to evaluate antiangiogenic activity. A total of 11 compounds were identified in both the extracts in GCMS analysis. The synthesized AgNCs were spherical shaped with an average size of 97.4 nm for AgAPE (Sox) and 64.3 nm for AgAPE (Mac). AgNCs possessed effective inhibition against Hep2C and KB cells. In Hep2C cells, AgAPE (Mac) revealed the highest SOD, catalase, GST activity and lower MDA content, whereas AgAPE (Sox) showed the highest GSH content. On the other hand, in KB cells, AgAPE (Sox) exhibited the higher SOD, GST activity, GSH content, and least MDA content, while AgAPE (Mac) displayed the highest levels of catalase activity. Docking analysis revealed maximum binding affinity of safrole and linoleic acid with selected targets. AgAPE (Sox), AgAPE (Mac) treatment profoundly reduced the thickness, branching, and sprouting of blood vessels in the chick embryos. This study indicates that A. precatorius-derived AgNCs have enhanced efficacies against cervical and oral carcinoma as well as against angiogenesis, potentially limiting tumour growth. [ABSTRACT FROM AUTHOR]

Biogenic silver nanoconjugates (AgNCs), derived from medicinal plants, have been widely explored in the field of biomedicines. AgNCs for the first-time were synthesized using ethyl acetate seed extracts of Abrus precatorius and their antiproliferative and antiangiogenic efficacies were evaluated against cervical and oral carcinoma. Ultraviolet–Visible spectrophotometry, dynamic light Scattering (DLS), and scanning electron microscopy (SEM) were used for characterization of AgNCs. Antiproliferative activity was investigated using MTT, DNA fragmentation and in-vitro antioxidant enzyme activity assays. In-vivo chick chorioallantoic membrane (CAM) model was used to evaluate antiangiogenic activity. A total of 11 compounds were identified in both the extracts in GCMS analysis. The synthesized AgNCs were spherical shaped with an average size of 97.4 nm for AgAPE (Sox) and 64.3 nm for AgAPE (Mac). AgNCs possessed effective inhibition against Hep2C and KB cells. In Hep2C cells, AgAPE (Mac) revealed the highest SOD, catalase, GST activity and lower MDA content, whereas AgAPE (Sox) showed the highest GSH content. On the other hand, in KB cells, AgAPE (Sox) exhibited the higher SOD, GST activity, GSH content, and least MDA content, while AgAPE (Mac) displayed the highest levels of catalase activity. Docking analysis revealed maximum binding affinity of safrole and linoleic acid with selected targets. AgAPE (Sox), AgAPE (Mac) treatment profoundly reduced the thickness, branching, and sprouting of blood vessels in the chick embryos. This study indicates that A. precatorius-derived AgNCs have enhanced efficacies against cervical and oral carcinoma as well as against angiogenesis, potentially limiting tumour growth. [ABSTRACT FROM AUTHOR]

Background: Arq-e-Keora is a liquid formulation of the Unani system of medicine and used since long for the management of weakness of heart, palpitations, etc. Objective: The study was carried out to generate a scientific data for its metabolite profiling, stability testing, pharmacokinetics, and pattern recognition analysis of Arq-e-Keora. Method: Arq-e-Keora has been prepared as water distillate of male wpadix of Pandanus odoratissimus L.f. TLC profiling of Arq-e-Keora was performed using hexane and acetone (7:3, v/v) as a solvent system. The metabolic profiling of volatile compounds was carried out using GC-MS. Pharmacokinetic analysis was performed through GC-MS to evaluate how quickly it absorbs and distributes in plasma. The pattern recognition analysis was performed in order to recognize the pattern and fate of metabolites in rat plasma up to 24h after single oral administration of Arq-e-Keora. Results: TLC and GC-MS analysis resulted in profiling of 11 and 21 metabolites, respectively. GC-MS analysis revealed that phenethyl alcohol, alpha-terpinolene, beta terpinene, alpha terpinene, beta fenchyl alcohol, hexadecanoic acid, and octadecanoic acid are the major metabolites found in Arq-e-Keora. The stability analysis showed that most of the compounds are stable at refrigerator temperature during their consumption. Pharmacokinetics data of phenethyl alcohol showed its absorption was rapid, with Tmax occurring within 1h after oral administration of Arq-e-Keora. In vivo pattern recognition analysis suggests that some metabolite expression was altered after its oral administration. Conclusions: As a result, our model could be used for quality, stability, and pharmacokinetic evaluation of various Unani formulations mentioned in Unani Pharmacopoeia of India. [ABSTRACT FROM AUTHOR]

Alzheimer's disease (AD) is one of the prominent causes for disability and lowered quality of life worldwide in elderly population. It has fostered immense burden to AD patients, families and society. Burgeoning progress in the field of pathogenesis over last two decades has persuaded the investigation of novel pharmacological therapeutics that focuses towards the pathophysiological events of AD. Miscellaneous clinical trials, development and testing of interventions aimed at various targets, such as anti‐tau and anti‐amyloid interventions, neurotransmitter modification, neuroprotection and anti‐neuroinflammation interventions, cognitive enhancement and interventions to palliate behavioural symptoms have been carried out. Despite massive efforts to find disease‐modifying therapies, there lingers a vital need for continuing the advancement in progress of the AD research. This review features the new developments of small molecule compounds that will be beneficial in evolution of new AD therapies. In particular, this review briefly describes summary of mechanistic causes chiefly associated with AD and focuses on medicinal approach via small molecule inhibitors that can manage cognitive impairment and dysfunction and may combat Alzheimer's development. [ABSTRACT FROM AUTHOR]

Objectives Limited treatment options are available for advanced stages of chronic myeloid leukaemia (CML). Moreover, patients' relapse after a short remission period, which prompts them to identify a potent drug with the least toxicity. An Unani herbal formulation, Itrifal-e-Aftimoon (IEA) is used for certain neurological disorders, however, its antitumor potential has not been reported yet in any malignancy, including CML. Methods The aqueous extract of IEA was characterized by HPLC/LC-MS and used alone or in combination with standard drug, imatinib in CML cell lines (K562, KU812) in vitro to assess its effect on cancer-associated parameters such as cytotoxicity, cell cycle, apoptosis, oxidative stress, inflammation, angiogenesis, and certain signalling pathways. Results LC–MS characterization of IEA showed the presence of antitumor compounds including catechin and caffeic acid. Treatment with IEA caused cytotoxicity and arrested cells in the sub-G0/G1 phase. Subsequent assays confirmed apoptosis-mediated cell death with mitochondrial membrane depolarization and alleviation of oxidative stress. IEA abrogates IL-6, VEGF, angiopoietin-2, and alters Th1/Th2 cytokines. IEA potentiated the effect of imatinib even at lower doses by affecting FAK/STAT/Akt/ERK pathways. Conclusion IEA possesses antitumor potential against CML and increases the efficacy of imatinib when used in combination, suggesting utilization of IEA as an adjuvant therapy for better management of CML in the future. [ABSTRACT FROM AUTHOR]

Background: There is an increasing global demand for traditional medicines because of their efficacy, ease of availability, and few or no side effects. The Unani medicines have long been used in India and abroad for various disorders and diseases. Arqiyat (Arq; distillate) is one of the most widely used Unani formulation prepared by simple distillation from single or combination drugs. Objective: In the present investigation, an attempt has been made to generate data for quality control and stability testing of Arq formulations of the Unani Pharmacopeia of India that includes only three Arq formulations. Method: Arq-e-Nana (AeN), Arq-e-Gazar (AeG), and Arq-e-Brinjasif (AeB) were prepared through hydrodistillation. Quality control and stability analysis were performed by using HPTLC and GC-MS. Results: Dichloromethane extract of AeB showed maximum of 10 bands at different retardation factor values; however, there are 7 bands in AeN as well as in AeG. GC-MS analysis showed presence of 10 metabolites in AeG, 8 in AeN, and 9 in AeB. Stability studies showed that the shelf life of Arq formulations would be enhanced at refrigeration (5 ± 2°C) conditions. Conclusions: The present study highlights quality control and stability analysis of Arq formulations of Unani Pharmacopeia of India using HPTLC and GC-MS. [ABSTRACT FROM AUTHOR]

This document is a correction notice for an article titled "Novel biogenic silver nanoconjugates of Abrus precatorius seed extracts and their antiproliferative and antiangiogenic efficacies" published in Scientific Reports. The correction addresses an error in the author list, where Tapan K. Chaudhuri was incorrectly listed as an author and has since been removed. The correction provides the revised author contributions section and states that the original article and supplementary information files have been corrected. The authors of the article are Amritpal Kaur, Yash Sharma, Gagandeep Singh, Anoop Kumar, Nutan Kaushik, Asim Ali Khan, and Kumud Bala. [Extracted from the article]

The Author Contributions section now reads: "Ap.K.: Methodology, Formal analysis, Validation, Data curation, Investigation, Writing - Original Draft. Correction to: I Scientific Reports i https://doi.org/10.1038/s41598-023-40079-8, published online 19 August 2023 The original version of this Article contained an error in the author list. [Extracted from the article]